IMMU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMMU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Immunomedics's enterprise value is $19,631.65 Mil. Immunomedics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was $-302.10 Mil. Therefore, Immunomedics's EV-to-EBITDA for today is -64.98.
The historical rank and industry rank for Immunomedics's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Immunomedics was -5.93. The lowest was -64.98. And the median was -12.22.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-05), Immunomedics's stock price is $87.86. Immunomedics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was $-1.730. Therefore, Immunomedics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Immunomedics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunomedics Annual Data | |||||||||||||||||||||
Trend | Jun10 | Jun11 | Jun12 | Jun13 | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Dec19 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -8.37 | -4.63 | -6.24 | -16.68 | -13.07 |
Immunomedics Quarterly Data | ||||||||||||||||||||
Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -8.42 | -10.34 | -13.07 | -7.99 | -24.84 |
For the Biotechnology subindustry, Immunomedics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Immunomedics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Immunomedics's EV-to-EBITDA falls into.
Immunomedics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 19631.649 | / | -302.096 | |
= | -64.98 |
Immunomedics's current Enterprise Value is $19,631.65 Mil.
Immunomedics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-302.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunomedics (NAS:IMMU) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Immunomedics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 87.86 | / | -1.730 | |
= | At Loss |
Immunomedics's share price for today is $87.86.
Immunomedics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Immunomedics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott A Canute | director | FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Peter Barton Hutt | director | |
Charles M Baum | director | C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
Khalid Islam | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Venbio Select Advisor Llc | director, 10 percent owner, other: See Remarks | 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Behzad Aghazadeh | director, 10 percent owner, other: See Remarks | C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Harout Semerjian | director, officer: President and CEO | 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950 |
Kurt J. Andrews | officer: Chief Human Resources Officer | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Bryan Ball | officer: Chief Quality Officer | 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Jared Freedberg | officer: General Counsel | 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Usama Malik | officer: Chief Business Officer & CFO | 300 THE AMERICAN WAY MORRIS PLAINS NJ 07950 |
Brendan Delaney | officer: Chief Commerical Officer | 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950 |
Lorettta M Itri | officer: Chief Medical Officer |
From GuruFocus
By PRNewswire PRNewswire • 08-21-2020
By Ishan Majumdar Ishan Majumdar • 07-08-2020
By Marketwired Marketwired • 07-14-2020
By GlobeNewswire GlobeNewswire • 09-19-2020
By Marketwired Marketwired • 08-17-2020
By PRNewswire PRNewswire • 09-15-2020
By Business Wire Business Wire • 06-25-2020
By PRNewswire PRNewswire • 09-21-2020
By GuruFocus Research GuruFocus Editor • 11-21-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.